Jeff Tong

Jeff Tong is a partner with Third Rock Ventures where he focuses on drug discovery and development across the portfolio. He is currently Chairman of the Board of Ambys Medicines and a board member of Nurix Therapeutics. Prior to joining Third Rock, Jeff was executive chairman of the board of Delinia until its acquisition by Celgene. From 2010 to 2015, Jeff was the president and CEO of Nora Therapeutics. Prior to that, he was a member of the founding management team at Infinity Pharmaceuticals where he led its corporate as well as product development activities. Over the course of his career, Jeff has raised significant capital from both equity markets and pharma partnerships, led teams from preclinical through phase 3 development, and developed integrated science/business strategies for building innovative biotechnology companies. Earlier in his career, Jeff worked at McKinsey & Co. and was a founding researcher at the Harvard Bauer Center for Genomics Research.

Jeff received his educational training at the interface of molecular biology, organic chemistry, and medicine and holds A.B. and M.M.S. degrees from Harvard College and Harvard Medical School, respectively, as well as A.M. and Ph.D. degrees from Harvard University.